secwatch.observer — SEC 8-K summary
======================================

Issuer:     Investview, Inc. (INVU)
CIK:        0000862651
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0001493152-24-043213
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Investview acquires Renu Labs and repurchases 121M shares (6.5% of outstanding)
-------------------------------------------------------------------------------

- Acquired Renu Laboratories, a manufacturer of proprietary health/beauty/wellness products; terms not disclosed.
- Expects acquisition to be revenue accretive as early as Q4 2024 - Q1 2025 via iGenius cross-selling.
- Repurchased 121M shares (6.5% of outstanding) from three non-affiliate shareholders at a discount to closing price.
- Repurchase resolves a dispute related to 2017 issuance; price payable in 10 equal quarterly installments.
- Plans to operate Renu under new myLife Wellness business unit leveraging its FDA-registered, cGMP facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/862651/000149315224043213/0001493152-24-043213-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/862651/000149315224043213/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-043213

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer